MannKind Corporation
As of Oct 22, 2026, MannKind is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $3.20, 48.5% below its 52-week high and below its 200-day average, which is falling.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MNKD early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MNKD among Biotechnology323rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …323 | MNKD | Stage 4 · wk 6 | 27 | −4.2% |
MannKind: quick answers
What stage is MannKind in?
As of Oct 22, 2026, MannKind (MNKD) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean
Is MannKind in an uptrend?
No. MannKind is in a Stage 4 downtrend. It trades 15.8% below its 200-day average, which is falling.
How far is MannKind from its 52-week high?
MannKind closed at $3.20 on Oct 22, 2026, 48.5% below its 52-week high of $6.21. Its 52-week low is $2.28.
How has MannKind performed over the past year?
As of Oct 22, 2026, MannKind is down 41.9% over the past year and down 42.9% so far in 2026.
Which sector and industry is MannKind in?
MannKind is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.